Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 28;108(4):699–702. doi: 10.1002/cpt.1879

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

PMC Copyright notice

Opportunities for clinical pharmacology and model‐informed drug development during the COVID‐19 pandemic. Applications in ( left panel ) dosage optimization of COVID‐19 therapies, ( middle panel ) informing benefit/risk for clinical trial participants, and ( right panel ) mitigating impact of clinical trial disruptions, with a Totality of Evidence approach. ACE, angiotensin converting enzyme; COVID‐19, coronavirus disease 2019; DDI, drug‐drug interaction; E‐R, exposure‐response; M&S, modeling and simulation; PBPK, physiologically‐based pharmacokinetics; PD, pharmacodynamics; PK, pharmacokinetics; QSP, quantitative systems pharmacology.